Safety and immunogenicity after a 30month boost of a subtype C ALVACHIV vCP2438 vaccine prime plus bivalent subtype C gp120 MF59 vaccine boost HVTN 100 A phase 12 randomized doubleblind placebocontrolled trial
| dc.article.end-page | 16 | en |
| dc.article.start-page | 1 | en |
| dc.citation.doi | 10.1371/JOURNAL.PGPH.0003319 | en |
| dc.contributor.author | Vimla Naicker | en |
| dc.contributor.author | Fatima Laher | en |
| dc.contributor.author | L Bekker | en |
| dc.contributor.author | K Seaton | en |
| dc.contributor.author | M Allen | en |
| dc.contributor.author | E et al | en |
| dc.contributor.author | Lynn Morris | en |
| dc.contributor.author | Nonhlanhla Mkhize | en |
| dc.date.accessioned | 2025-03-29T17:46:10Z | |
| dc.faculty | FACULTY OF HEALTH SCIENCES | en |
| dc.identifier.citation | DOAJ | en |
| dc.identifier.uri | https://hdl.handle.net/10539/44505 | |
| dc.journal.title | Safety and immunogenicity after a 30month boost of a subtype C ALVACHIV vCP2438 vaccine prime plus bivalent subtype C gp120 MF59 vaccine boost HVTN 100 A phase 12 randomized doubleblind placebocontrolled trial | en |
| dc.journal.volume | 4 | en |
| dc.title | Safety and immunogenicity after a 30month boost of a subtype C ALVACHIV vCP2438 vaccine prime plus bivalent subtype C gp120 MF59 vaccine boost HVTN 100 A phase 12 randomized doubleblind placebocontrolled trial | en |
| dc.type | Journal Article | en |
Files
Original bundle
1 - 1 of 1
- Name:
- Journal Article.pdf
- Size:
- 2.95 MB
- Format:
- Adobe Portable Document Format
- Description:
- Bitstream uploaded by REST Client